unknown
Stage
About
Aldatu Biosciences develops molecular diagnostic assays using its PANDAA adaptive PCR platform to detect and genotype highly variable infectious disease pathogens (e.g., SARS-CoV-2, Lassa virus, Ebola, and HIV drug resistance). The company provides PCR-based assay products and laboratory testing services for outbreak preparedness and infectious disease surveillance.
Explore Aldatu Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.